Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Comparison of immunochemical fecal occult blood tests for colorectal cancer screening

A study in May's issue of Gastroenterology compares immunochemical Fecal Occult Blood Tests for Colorectal Cancer Screening

News image

Quantitative fecal immunochemical tests identify individuals with colorectal cancer with greater levels of accuracy than guaiac tests.

Dr Thibaut Raginel and colleagues from  France compared the performances of 2 fecal immunochemical tests in a population undergoing screening for colorectal cancer.

The research team collected fecal samples from 19,797 individuals in France who participated in a colorectal cancer screening program, from 2009 through 2011.

Samples were analyzed using the Magstream and OC Sensor fecal immunochemical tests, as well as the Hemoccult II guaiac test.

The doctors reported that colonoscopies were performed for patients with positive results from all 3 tests.

The cut-off values for levels of hemoglobin in buffer and stools were 55 ng/mL and 180 μg/g for the Magstream and 150 ng/mL, and 30 μg/g for the OC Sensor, respectively.

The doctors found that the results from the fecal immunochemical tests were compared with those from the guaiac test for cut-off values for stool samples, positivity rates, and the receiver operating characteristic curve values.

The numbers needed to screen and the numbers needed to scope to detect an advanced neoplasia were calculated.

Numbers needed to screen were 66 for a 1-sample Magstream fecal immunochemical tests
Gastroenterology

A positive test result was found in 1224 participants.

The research team reported 1075 underwent a colonoscopy examination.

Of these, 334 were found to have advanced neoplasia.

Considering the cut-off values associated with the positivity rate of Hemoccult II, the numbers needed to screen were 239 for Hemoccult II, 166 for a 1-sample Magstream fecal immunochemical tests, and 129 for a 1-sample OC Sensor fecal immunochemical tests.

The team found that the numbers needed to scope were 3.3, 2.3, and 1.8, respectively.

For the same false-positive rate as Hemoccult II, the true-positive rates for Magstream and OC Sensor fecal immunochemical tests were 0.65% and 0.90% respectively, compared with 0.42% for Hemoccult II.

The OC Sensor fecal immunochemical tests had a greater area under the receiver operating characteristic curve value than the Magstream fecal immunochemical tests.

Dr Thibaut's team commented "Based on results from a large, population-based study, the OC Sensor fecal immunochemical tests identifies patients with colorectal cancer with greater accuracy than the Magstream fecal immunochemical tests."

Gastroenterology 2013: 144(5) :918-925
10 May 2013

Go to top of page Email this page Email this page to a colleague

 04 May 2015

Advanced search
 04 May 2015 
Endoscope storage and microbial colonization
 04 May 2015 
Stress resilience and peptic ulcer disease
 04 May 2015 
Menarche and NAFLD
 01 May 2015 
Sleep and physical activity measured in Crohn's
 01 May 2015 
NAFLD progression from steatosis to fibrosing-steatohepatitis
 01 May 2015 
Dietary supplement hepatotoxicity
 30 April 2015 
Botulinum toxin A for the treatment of obesity
 30 April 2015 
Neoadjuvant chemoradiotherapy for esophageal cancer
 30 April 2015 
Risk factors for primary sclerosing cholangitis
 29 April 2015 
Liver enzyme elevations after anti-TNF therapy in IBD

 29 April 2015 
Hepatocellular carcinoma surveillance in HBV
 29 April 2015 
Response to sorafenib in hepatocellular carcinoma
 28 April 2015 
Risk factors of hepatocellular carcinoma
 28 April 2015 
Clinical outcomes after esophagectomy
 28 April 2015 
Alcohol drinking and risk of liver cirrhosis
 23 April 2015 
Gut microbiota modulation for alcoholic liver disease
 23 April 2015 
Moderate sodium restriction diet in cirrhosis
 23 April 2015 
Gastroesophageal junction disruption and obesity
 22 April 2015 
Hepatitis and mortality in hospitalized patients
 22 April 2015 
Magnetic sphincter augmentation for GERD
 22 April 2015 
Drug, herbal and dietary supplement hepatotoxicity
 21 April 2015 
Risk factors of postpartum bowel changes
 21 April 2015 
Tracking colonoscopy surveillance intervals
 21 April 2015 
PPI increases risk of cryptogenic liver abscess
 20 April 2015 
IBS after traveller's diarhea
 20 April 2015 
Adherence to Hep C treatments
 20 April 2015 
Economic impact of C. diff infection
 17 April 2015 
Synchronous colorectal advanced neoplasia
 17 April 2015 
PNPLA3 polymorphisms and NAFLD risk
 17 April 2015 
MELD score and colorectal resection
 16 April 2015 
Bleeding risk in colonic diverticulosis
 16 April 2015 
Minority use of high-volume hospitals for colorectal cancer
 16 April 2015 
Sleep and IBD
 15 April 2015 
Treatment of hepatocellular carcinoma
 15 April 2015 
Score predicts malignant bile duct obstruction
 15 April 2015 
Increased risk of Barrett esophagus
 14 April 2015 
Improving colorectal cancer screening uptake
 14 April 2015 
Colorectal cancer presenting under the age of 50
 14 April 2015 
Functional constipation vs constipation predominant IBS
 13 April 2015 
Fecal transplant for C. difficile
 13 April 2015 
Immune based treatments for HCC
 13 April 2015 
CRP and acute diverticulitis
 10 April 2015 
Adjuvant therapy after rectal cancer
 10 April 2015 
Viral outcomes in HCV infection
 10 April 2015 
Hypnotherapy for IBS
 09 April 2015 
Male IBD patients wishing to conceive
 09 April 2015 
Screening programs based on the fecal immunochemical test
 09 April 2015 
Management of esophageal food impaction
 08 April 2015 
Ambulatory hemorrhoidal surgery
 08 April 2015 
Iron fortification and gut inflammation
 08 April 2015 
Nonceliac gluten sensitivity
 07 April 2015 
Treatment of Hep C virus
 07 April 2015 
Interventions for eosinophilic esophagitis
 07 April 2015 
Endoscopic managements of GI bleeds
 06 April 2015 
Risk stratifying Barrett's esophagus
 06 April 2015 
Cost-effectiveness of HCV
 06 April 2015 
Treatment for rectal cancer
 03 April 2015 
Vitamin D deficiency and Hep B outcomes
 03 April 2015 
Hepatocellular carcinoma surveillance in cirrhosis
 03 April 2015 
Predicting advanced cancer in Barrett's

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us